Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: Results of two phase III trials

Vincent Meininger, Gilbert Bensimon, Walter G. Bradley, Benjamin R. Brooks, Patrice Douillet, Andrew A. Eisen, Lucette Lacomblez, P. Nigel Leigh, Wim Robberecht

Research output: Contribution to journalArticle

97 Scopus citations

Abstract

Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal motor neuron disease. We carried out two randomized, double-blind, placebo-controlled, multi-centre, multi-national studies with xaliproden (a drug with neurotrophic effect) to assess drug efficacy and safety at two doses. Patents with clinically probable or definite ALS of more than 6 months and less than 5 years duration were randomly assigned to placebo, 1 mg or 2 mg xaliproden orally once daily as monotherapy in Study 1 (n=867); or to the same regimen with addition of riluzole 50 mg bid background therapy in Study 2 (n=1210 patients). The two primary endpoints were defined as: 1. Time to death, tracheostomy, or permanent assisted ventilation (DTP), and 2. Time to vital capacity (VC)<50% or DTP before (log-rank test) and after adjustment using a Cox proportional hazard model for prespecified prognostic factors. Secondary endpoints were rates of change of various functional measures. In Study 1, primary outcome measures did not reach statistical significance. For the 2 mg group, for time to VC<50% analysis (without DTP) a significant 30% RRR was obtained (95% confidence interval [CI]: 8.46, P=0.009). In Study 2, no significant results were obtained. However, there was a trend in favour of add-on 1 mg dose xaliproden vs. placebo (RRR 15% [-6.31, ns] for time to VC<50%; RRR 12% [Cl: -6.27, ns] for time to VC<50% or DTP). Adjusted RR ratios were consistently more favourable for the xaliproden groups. Tolerability was good, and dose-dependent side effects were largely associated with the serotonergic properties of xaliproden. An effect of xaliproden on functional parameters, especially VC, was noted. Although this effect did not reach statistical significance, xaliproden had a small effect on clinically noteworthy aspects of disease progression in ALS.

Original languageEnglish (US)
Pages (from-to)107-117
Number of pages11
JournalAmyotrophic Lateral Sclerosis and Other Motor Neuron Disorders
Volume5
Issue number2
DOIs
StatePublished - Jun 1 2004

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: Results of two phase III trials'. Together they form a unique fingerprint.

  • Cite this